Lyudmila Bazhenova, MD, Discusses Potential for Trials Featuring Combination IO/Targeted Therapy for EGFR Exon 20+ and Wild Type NSCLC
October 22, 2021

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

Annamycin Demonstrates Positive Clinical Activity for Soft Tissue Sarcoma Lung Metastases
October 22, 2021

The interim results of a phase 1b/2 trial showed that patients with soft tissue sarcoma and lung metastases who were treated with annamycin experienced positive clinical activity.

Investigators Announce Expansion to Phase 2 for Trial of BXCL701/Pembrolizumab Combo in Small Cell Neuroendocrine Prostate Cancer
October 22, 2021

BXCL701 and pembrolizumab may resolve the need for FDA-approved therapies for patients with small cell neuroendocrine prostate cancer, according to investigators.

Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?
October 22, 2021

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.

A Case of Transplant-Eligible NDMM: First-Line Treatment Options
October 22, 2021

After reviewing the case of a patient with transplant-eligible newly-diagnosed multiple myeloma, experts consider optimal selection of first-line treatment.

Considering the Role of NRG1 Fusions in Lung Cancer Management
October 22, 2021

Practical considerations regarding the role of NRG1 fusions in lung cancer management and how that has been informed by the eNRGy1 global registry study.

Advances in Metastatic Castration-Resistant Prostate Cancer
October 22, 2021

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

Rucaparib for Prostate Cancer
October 22, 2021

Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.

Precision Medicine in Head and Neck Cancer
October 22, 2021

Key takeaways from a paper that evaluated the efficacy of tipifarnib in recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

ctDNA as a Biomarker in CRC
October 22, 2021

An overview of what is currently understood about the use of ctDNA assays to help guide treatment decisions when managing patients with colorectal cancer undergoing resection of metastases.